Published in Medical Letter on the CDC and FDA, May 16th, 2004
Apokyn was given priority review because injectable apomorphine is the first therapy approved to treat these episodes acutely (during the episode). Apokyn was also designated as an orphan product.
Within 3-5 years of treatment with standard Parkinson drug treatments, about 10% of patients experience episodes of hypomobility (e.g., inability to rise from a chair, to speak or to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.